Date: 2011-07-06
Type of information: Capital increase
Company: Antisense Pharma - now Isarna Therapeutics (Germany)
Investors: MIG Funds 2, 3 and 9
GAF
Amount: € 8 million
Funding type: capital increase
Planned used: Antisense Pharma is preparing the start a further phase II/III study with tradebersen (DNA-oligonucleotide that binds specifically to transforming growth factor beta 2 (TGF-ß2) messenger RNA, thereby preventing translation into the protein TGF-ß2). This pivotal study is an international clinical trial.
Others: Antisense Pharma has announced that MIG Funds 2, 3 and 9 as well as GAF have increased their share capital by approximately € 8 million euro.
Therapeutic area: Cancer - Oncology - Ophtalmological diseases - Fibrotic diseases
